Skip to content

A single-center, randomized, controlled clinical study of the effects of modified and traditional BII+Braun digestive tract reconstruction methods on quality of life after radical gastrectomy for distal gastric cancer

A single-center, randomized, controlled clinical study of the effects of modified and traditional BII+Braun digestive tract reconstruction methods on quality of life after radical gastrectomy for distal gastric cancer

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800016131
Enrollment
Unknown
Registered
2018-05-14
Start date
2018-05-14
Completion date
Unknown
Last updated
2018-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer

Interventions

test team: Modified technique
control group: Traditional technique

Sponsors

Affiliated Cancer Hospital of Harbin Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Aged 18 to 75 years; (2) Gastric lesions were diagnosed as gastric adenocarcinoma by endoscopic biopsy.[Papillary adenocarcinoma (pap), tubular adenocarcinoma (tub),mucinous adenocarcinoma (muc), signet-ring cell carcinoma (sig), poorly differentiated adenocarcinoma (por)]; (3) The preoperative clinical stage is T1-4a, N0-3, M0(According to AJCC-7thTNM tumor stage); (4) It is expected that the results of R0 surgery can be obtained by performing distal gastrectomy and D2 lymph node dissection; (5) Preoperative ECOG performance status score 0/1; (6) Nutrition risk screening (NRS2002); (7) Preoperative ASA score I-III; (8) Patient informed consent.

Exclusion criteria

Exclusion criteria: 1. Pregnancy or breastfeeding women; 2. Severe mental illness; 3. History of upper abdominal surgery (except laparoscopic cholecystectomy history); 4. History of gastric surgery (including ESD/EMR for gastric cancer); 5. 3 years of history of other malignant diseases; 6. Gastric cancer patients who have undergone neoadjuvant treatment or recommend neoadjuvant treatment; 7. A history of unstable angina or myocardial infarction within 6 months; 8. History of cerebral infarction or cerebral hemorrhage within 6 months; 9. There is a history of sustained systemic corticosteroid treatment within 1 month; 10. Needs simultaneous surgical treatment of other diseases; 11. Gastric cancer complications (bleeding, perforation, obstruction) require emergency surgery; 12. Pulmonary function test FEV<1 predicted value 50%.

Design outcomes

Primary

MeasureTime frame
GSRS;

Countries

China

Contacts

Public ContactYingwei Xue

Affiliated Cancer Hospital of Harbin Medical University

doctormayan@163.com+86 13304646901

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026